Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1691)	8/1/2006 12:47:44 PM
From: Jim Oravetz	Respond to of 1826

MGI Pharma Gets Europe Orphan-Drug Status For Dacogen DOW JONES NEWSWIRES August 1, 2006 9:50 a.m. MGI Pharma Inc. (MOGN) has received orphan designation from the European Medicines Agency for Dacogen for injection for the indication of acute myeloid leukemia. The company said the orphan-drug designation was established by the EMEA to encourage the development of treatments for rare, life-threatening medical conditions. It said this designation may provide 10 years of market exclusivity in the EU following marketing approval. The Bloomington, Minn. biopharmaceutical company said it is conducting a Phase III pivotal trial to evaluate Dacogen in patients with AML. As well, additional Phase II studies are underway to evaluate alternative dosing regimens for Dacogen in patients with MDS, AML and chronic myelogenous leukemia, or CML.